INFLUENCE OF EXERCISE ON BIOMARKERS OF MUSCLE IMMUNE RESPONSE AND MITOCHONDRIAL DAMAGE AND THEIR RELATIONSHIP WITH CANCER-RELATED FATIGUE (CRF): A URCC NCORP STUDY

FEASIBILITY OF HOME VS. HOSPITAL BASED RESISTANCE TRAINING FOR ADVANCED CANCER PATIENTS: A PHASE II TRIAL

A RANDOMIZED PHASE 2 PLACEBO CONTROLLED TRIAL OF CLOBETASOL RINSE FOR TREATMENT OF ORAL CHRONIC GRAFT-VERSUS-HOST DISEASE

SAFETY, TOLERABILITY, EFFICACY, AND IMMUNOGENICITY OF INACTIVATED VZV VACCINE (ZVIN) IN RECIPIENTS OF AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTS (AUTO-HSCTS)

PHASE 3 EFFICACY AND SAFETY STUDY OF PALONOSETRON IV INFUSION VERSUS IV BOLUS FOR CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING (CINV) PROPHYLAXIS FOLLOWING HIGHLY EMETOGENIC CHEMOTHERAPY (HEC)

ROLAPITANT FOR THE PREVENTION OF NAUSEA IN PATIENTS RECEIVING CISPLATIN- OR CARBOPLATIN-BASED CHEMOTHERAPY: ALTERNATIVE METHODS FOR EVALUATING NAUSEA

EFFECTIVENESS OF LAWSONIA INERMIS (HENNA) FOR THE MANAGEMENT OF PALMAR-PLANTAR ERYTHRODYSESTHESIA: PRELIMINARY RESULTS FROM A RANDOMISED CONTROLLED TRIAL

FIRST-LINE RIBOCICLIB + LETROZOLE IN POSTMENOPAUSAL WOMEN WITH HORMONE RECEPTOR–POSITIVE (HR+), HER2− ADVANCED BREAST CANCER (ABC): MONALEESA-2 SAFETY RESULTS

CEBRANOPADOL, A NOVEL FIRST-IN-CLASS ANALGESIC DRUG CANDIDATE: EFFICACY, SAFETY, TOLERABILITY IN PATIENTS WITH CANCER-RELATED CHRONIC PAIN

CEBRANOPADOL, A NOVEL FIRST-IN-CLASS ANALGESIC DRUG CANDIDATE: FIRST EXPERIENCE IN PATIENTS WITH CANCER-RELATED PAIN TREATED FOR UP TO 26 WEEKS